Search results
Showing 16 to 30 of 33 results for obinutuzumab
Obinutuzumab for treating serologically active extra-renal lupus [ID6670]
Awaiting development Reference number: GID-TA11886 Expected publication date: TBC
Lenalidomide with rituximab for previously treated follicular lymphoma (TA627)
Evidence-based recommendations on lenalidomide (Revlimid) with rituximab for previously treated follicular lymphoma (grade 1 to 3A) in adults.
In development Reference number: GID-TA11768 Expected publication date: 03 September 2026
Find out which guidance and quality standards are awaiting development
View a complete list of all our guidance, NICE advice and quality standards currently in development
Mosunetuzumab for treating relapsed or refractory follicular lymphoma (TA892)
Evidence-based recommendations on mosunetuzumab (Lunsumio) for relapsed or refractory follicular lymphoma in adults.
Awaiting development Reference number: GID-TA11910 Expected publication date: TBC
Venetoclax with ibrutinib and obinutuzumab for untreated chronic lymphocytic leukaemia ID1270
Discontinued Reference number: GID-TA10211
Evidence-based recommendations on glofitamab (Columvi) for treating relapsed or refractory diffuse large B-cell lymphoma in adults after 2 or more systemic treatments.
Axicabtagene ciloleucel for treating relapsed or refractory follicular lymphoma (TA894)
Evidence-based recommendations on axicabtagene ciloleucel (Yescarta) for relapsed or refractory follicular lymphoma in adults.
Thousands living with lupus offered hope from twice-yearly infusion
NICE approves breakthrough combination treatment that restores normal kidney function in almost half of patients with lupus nephritis.
Polatuzumab vedotin in combination for untreated diffuse large B-cell lymphoma (TA874)
Evidence-based recommendations on polatuzumab vedotin (Polivy) with rituximab, cyclophosphamide, doxorubicin and prednisolone for untreated diffuse large B-cell lymphoma in adults.
Venetoclax with obinutuzumab for untreated chronic lymphocytic leukaemia (TA663)
This guidance has been updated and replaced by NICE technology appraisal guidance 1119.
Evidence-based recommendations on glofitamab (Columvi) plus gemcitabine and oxaliplatin for treating relapsed or refractory diffuse large B-cell lymphoma not otherwise specified in adults.
Obinutuzumab with bendamustine for treating follicular lymphoma refractory to rituximab (TA472)
This guidance has been updated and replaced by NICE technology appraisal guidance 629.